California Company Helps Form New Brain Cells

By: Dylan Sikes – AllPennyStocks.com News

Thursday, January 31, 2019

Medical advances are sometimes large and momentous, sometimes relatively small but still significant. It would seem that the development offered up Thursday by San Francisco-based VistaGen Therapeutics (NASDAQ:VTGN) would be of the latter category.

VTGN, a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system (CNS) diseases and disorders with high unmet need, announced data indicating that its orally available CNS drug candidate, AV-101, promotes what is called hippocampal neurogenesis, by which new neurons are formed in a region of the brain that involves high-level functions such as emotions, memory, and spatial navigation and exploration

According to VistaGen CEO Shawn Singh, “The development of new neurons is a vital part of our mental growth during adulthood, and the exciting results of these non-clinical studies highlight AV-101’s potential to promote adult hippocampal neurogenesis.”

Singh continued, “We believe these results are potentially far-reaching, especially given that enhanced hippocampal cell proliferation provides protection against stress-related psychiatric disorders, including depression.”

The development also stimulated trading in the stock, VTGN gaining 14 cents Wednesday afternoon, or 9.2%, to head into the final hour of trade at $1.66, on volume of 650,000 shares.

Copyright © 2019 AllPennyStocks.com. All rights reserved. Republication or redistribution of AllPennyStocks.com's content is expressly prohibited without the prior written consent of AllPennyStocks.com. AllPennyStocks.com shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon